Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Brii Bio Publishes 2022 Environmental, Social and Governance Report 2023-04-28 09:00
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results 2023-03-24 13:33
Brii Biosciences Provides Update on Strategic Clinical Development Progress 2022-12-27 20:00
Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022 2022-10-19 20:00
Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression 2022-09-26 20:00
Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum 2022-09-01 07:30
Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results 2022-08-24 07:30
Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head 2022-08-23 07:30
Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants 2022-07-27 07:00
Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China 2022-07-19 12:34
Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer 2022-07-13 19:00
Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China 2022-07-07 07:10
Brii Biosciences Exercises Option for Vir Biotechnology's VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China 2022-07-04 07:10
Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China 2022-06-09 19:00
1 2